

MHRA

151 Buckingham Palace Road
London SW1W 9SZ
United Kingdom

mhra.gov.uk

Dr Birgit Whitman
UNIVERSITY OF BRISTOL
RESEARCH ENTERPRISE & DEVELOPMENT DEPARTMENT
BRISTOL
BS8 1TH
UNITED KINGDOM

19/12/2013

Dear Dr Birgit Whitman

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	03299/0015/001-0003
Eudract Number:	2012-000851-15
Product:	Prednisolone
Protocol number:	UoB1581
Substantial Amendment Code Number:	Code Number: UoB1581
Version:	1.4
Date:	2013/09/23

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 26/11/2013.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**